Subsidiary YKYY029 injection of Youcare Pharmaceutical Group (688658.SH) has obtained FDA clinical trial approval.

date
23/07/2025
avatar
GMT Eight
Yuekang Pharmaceutical Industry (688658.SH) issued an announcement, the company's subsidiary Beijing Yuekang Innovation Pharmaceutical Technology Co., Ltd...
Youcare Pharmaceutical Group (688658.SH) announced that its subsidiary, Beijing Yuesheng Pharmaceutical Technology Co., Ltd. (referred to as "Yuesheng"), recently received a notice from the U.S. Food and Drug Administration (FDA) approving the clinical trial of YKYY029 injection for the treatment of hypertension (Study May Proceed Letter, IND number: 176571). YKYY029 injection is a small interfering ribonucleic acid (siRNA) drug targeting the AGT gene, independently developed by Yuesheng and the company's wholly-owned subsidiary, Hangzhou Tianlong Pharmaceutical Co., Ltd. It has a novel sequence and utilizes the company's independently developed siRNA sequence modification template and GalNAc delivery system, granting the company global exclusivity.